These data corroborated with the JAK3 inhibitor findings above that BRRF1 and IL-22 cooperate through the JAK3/STAT3 pathway to trigger the expression of BTN2A1 in these NPC cell lines. The gene discussed is JAK3; the disease is nasopharyngeal carcinoma.